KEY TAKEAWAYS
- The study aimed to investigate the association between the CTSG N125S polymorphism and BCC’s pathogenesis.
- Researchers concluded that the CTSG N125S polymorphism is not associated with BCC’s pathogenesis.
Cathepsin G (CTSG) has been identified as an inhibitor of breast, bladder, and colorectal cancers (CRC). The G allele of the N125S (A/G, rs45567233) functional polymorphism of the CTSG gene confers increased serum CTSG activity and has been associated with cardiovascular and neurovascular diseases.
Anna Douka and the team aimed to examine the possible correlation between the pathogenesis of basal cell carcinoma (BCC) and the functional polymorphism CTSG N125S.
They performed an inclusive analysis on 197 DNA samples, including 98 BCC patients and 99 control samples of Greek origin. The CTSG N125S polymorphism was molecularly genotyped using PCR amplification, followed by enzyme digestion and agarose gel electrophoresis of the amplified DNA fragments.
The statistical analysis revealed no significant variance in genotypic and allelic frequencies between the patient and control groups, indicating a lack of association between the CTSG N125S polymorphism and basal cell carcinoma susceptibility.
The study concluded that comprehensive analysis revealed no significant association between the CTSG N125S polymorphism and BCC’s pathogenesis, suggesting that this genetic variant may not play a substantial role in BCC susceptibility or development.
No funding information was provided.
Source: https://pubmed.ncbi.nlm.nih.gov/38677729/
Douka A, Gintoni I, Derka S, et al. (2024). “Investigation of Genetic Association Between a High Activity Variant of Cathepsin G and Risk for Basal Cell Carcinoma.” Anticancer Res. 2024 May;44(5):2091-2094. doi: 10.21873/anticanres.17013. PMID: 38677729.
